



STATE MEDICAID DUR BOARD MEETING  
 THURSDAY, October 10, 2013  
 7:00 a.m. to 8:30 a.m.  
 Cannon Health Building  
 Room 114



## MINUTES

**Board Members Present:**

Tony Dalpiaz, PharmD.  
 George Hamlin, PharmD  
 Mr. Kumar Shah  
 Michael Symond, M.D.

Jennifer Brinton, MD  
 Mark Balk, PharmD.  
 Kyle Jones, M.D.  
 Keith Tolman, M.D.

**Board Members Excused:**

Susan Siegfroid, M.D.

Jay Aldus, DDS

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Robyn Seely, PharmD.  
 Trevor Smith C.Ph.T.  
 Merelynn Berrett, R.N.

Lisa V Hunt, R.Ph.  
 Richard Sorenson, R.N.

**Other Individuals Present:**

Scott Larson, BMS  
 Bryan Larson, UofU  
 MaryKay Queener, J&J  
 Clayne Garrett, BIPI

Joanita Lake, UofU  
 Charissa Anne, J&J  
 Brooks Hubbard, BIPI

---

**Meeting conducted by: Tony Dalpiaz, Pharm.D.**

---

1. **Welcome** – Tony Dalpiaz opened the meeting.
2. **Housekeeping** – Robyn Seely announced that there will be no petitions following the meeting.
3. **P&T Committee report** – Lisa Hunt addressed the board she reported that the P&T committee will be reviewing IBS agents. She then provided a tentative schedule for future P&T meeting topics.
4. **Approval of prior meeting minutes** – Keith Tolman made a motion to approve the September minutes as written. Jennifer Brinton seconded the motion. The motion was approved unanimously.
5. **Invokana** – Joanita Lake presented the clinical evidence prepared by the University of Utah Drug Information Center.

6. **Public Comment** – MaryKay Queener, (J&J) provided information about Invokana and requested that it be available to Medicaid patients.

## 7. **Board Discussion**

- Keith Tolman inquired about any special traits this drug has over other drugs considering many of the side effects.
- Joanita Lake said that this drug does have good traits and qualities for some patients but it is for the board to consider.
- Mike Symond said that this drug should be used only in special circumstances for special patients in limited usage circumstances.
- Keith Tolman asked about if liver disease studies with Invokana.
- Robyn Seely shared some information from the drug insert about hepatic issues.
- Robyn Seely presented information about other state's coverage and any prior authorization criteria of the product along with the ACO's coverage standing with the drug.
- Robyn Seely provided a draft of prior authorization criteria sheet for the drug Invokana for the board to review
- Keith Tolman asked why put a PA on a drug like this where it is similar to other drugs used. He added that it can make it difficult for prescribers to provide care for patients with the added hoops to jump through. He said we need to trust prescribers.
- Robyn Seely said that due to new adverse effects, and a new mechanism of action that aren't present in other similar drugs, the PA is needed. She encouraged the board to continue to discuss and decide on the PA criteria.
- Jennifer Brinton asked Keith Tolman if he feels there should be no prior authorization or a more limited prior authorization.
- Keith Tolman said he would prefer no prior authorization.
- Jennifer Brinton said that there may not be a need for a prior authorization since there has been such low usage of the drug (only 2 patients). She said it may be better to say no PA, but to monitor usage to watch for inappropriate usage
- Mark Balk said that the goal of the DUR board is to look for drugs that have potential to be misused or have safety or potentially dangerous side effects. He also looked at the comparisons of other drugs in the antidiabetic class.
- The DPP-4 class have PA criteria, but the TZD class doesn't have a PA.
- Mark Balk gave two ideas about how to proceed with the criteria with the class. He said to either make the criteria for all the antidiabetic agents with the same criteria, or to remove the criteria from all the drugs in the class, and watch usage for nine months for any problems.
- Robyn Seely said that she is not sure if she is allowed to make changes to a drug criteria if the drug was not included on the agenda to allow for any public comment.
- It was agreed to include discussion of antidiabetic agents with next month's topics.
- Mark Balk asked about the number prior authorization for drugs in the class.
- Richard Sorenson said that there is not a lot of DPP-4 requests. Usually the requests say that the patient had failed on one of the preferred agents.
- Joanita Lake said that data from other states show that the agents usually require criteria including a step through metformin/sulfonylureal drugs.
- Mark Balk said that they all should be at the same level, either require a PA or remove the

PA from the all, Joanita Lake agreed.

- Robyn Seely said that she will research usage and drug therapy of clients on these drugs, to decide as a board in that manner to proceed with a step through, or leave the drugs open.
- Kumar Shah said it would be wise to not rush a decision with criteria, as these drugs are new and should involve a slower process to avoid mistakes.
- Mark Balk makes a motion that at present time, there should be no PA on Invokana, and to follow-up next month by looking at the DPP-4 criteria. George Hamlin seconds the motion. All in favor.

#### **8. Meeting adjourned**

The next DUR Board meeting is scheduled for Thursday, November 14, Tudorza.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)